Cargando…

Cell cycle plasticity driven by MTOR signaling: Integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC), like many KRAS-driven tumors, preferentially loses CDKN2A that encodes an endogenous CDK4/6 inhibitor to bypass the RB-mediated cell cycle suppression. Analysis of a panel of patient-derived cell lines and matched xenografts indicated that many pancreatic can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knudsen, Erik S., Kumarasamy, Vishnu, Ruiz, Amanda, Sivinski, Jared, Chung, Sejin, Grant, Adam, Vail, Paris, Chauhan, Shailender S., Jie, Tun, Riall, Taylor S., Witkiewicz, Agnieszka K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499706/ https://www.ncbi.nlm.nih.gov/pubmed/30696953 http://dx.doi.org/10.1038/s41388-018-0650-0

Ejemplares similares

CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
por: Knudsen, Erik S., et al.
Publicado: (2022)

Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature
por: Knudsen, Erik S., et al.
Publicado: (2017)

Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer
por: Kumarasamy, Vishnu, et al.
Publicado: (2019)

The transcriptome of CDK4/6 inhibition
por: Knudsen, Erik S., et al.
Publicado: (2017)

Interrogating Mutant Allele Expression via Customized Reference Genomes to Define Influential Cancer Mutations
por: Grant, Adam D., et al.
Publicado: (2019)

Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer
por: Knudsen, Erik S., et al.
Publicado: (2016)

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
por: Franco, Jorge, et al.
Publicado: (2014)

CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2014)

Correction: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2021)

Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities
por: Franco, Jorge, et al.
Publicado: (2020)

Determinants of response to CDK4/6 inhibitors in the real-world setting
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2023)

Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility
por: Knudsen, Erik S, et al.
Publicado: (2018)

Composite Analysis of Immunological and Metabolic Markers Defines Novel Subtypes of Triple Negative Breast Cancer
por: Adams, Thomas A., et al.
Publicado: (2017)

A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
por: Weinberg, Benjamin A., et al.
Publicado: (2020)

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2015)

Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center
por: Knudsen, Erik S, et al.
Publicado: (2022)

Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions
por: Witkiewicz, Agnieszka K, et al.
Publicado: (2014)

KNIME-CDK: Workflow-driven cheminformatics
por: Beisken, Stephan, et al.
Publicado: (2013)

CDK1 structures reveal conserved and unique features of the essential cell cycle CDK
por: Brown, Nicholas R., et al.
Publicado: (2015)

CDK Substrate Phosphorylation and Ordering the Cell Cycle
por: Swaffer, Matthew P., et al.
Publicado: (2016)

CDK1: beyond cell cycle regulation
por: Liao, Hongwei, et al.
Publicado: (2017)

Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders
por: Gipson, Tanjala T., et al.
Publicado: (2012)

CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: Duration of cell cycle arrest and MTOR activity determine geroconversion
por: Leontieva, Olga V, et al.
Publicado: (2013)

Cell Cycle Control by a Minimal Cdk Network
por: Gérard, Claude, et al.
Publicado: (2015)

Association Between Noninvasive Fibrosis Markers and Postoperative Mortality After Hepatectomy for Hepatocellular Carcinoma
por: Maegawa, Felipe B., et al.
Publicado: (2019)

Naples in the time of cholera, 1884–1911
por: Riall, Lucy
Publicado: (1997)

A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas
por: Hadjadj, Djihad, et al.
Publicado: (2017)

Dynamics of Cdk1 Substrate Specificity during the Cell Cycle
por: Kõivomägi, Mardo, et al.
Publicado: (2011)

Rising Cyclin-CDK Levels Order Cell Cycle Events
por: Oikonomou, Catherine, et al.
Publicado: (2011)

Getting to S: CDK functions and targets on the path to cell-cycle commitment
por: Fisher, Robert P.
Publicado: (2016)

CDK4/6 inhibition: the late harvest cycle begins
por: Goel, Shom, et al.
Publicado: (2016)

Cell adhesion is regulated by CDK1 during the cell cycle
por: Jones, Matthew C., et al.
Publicado: (2018)

Cdk5 and aberrant cell cycle activation at the core of neurodegeneration
por: Requejo-Aguilar, Raquel
Publicado: (2022)

Hepatic Tumor Cell Morphology Plasticity under Physical Constraints in 3D Cultures Driven by YAP–mTOR Axis
por: Frtús, Adam, et al.
Publicado: (2020)

CDK1 substitutes for mTOR kinase to activate mitotic cap-dependent protein translation
por: Shuda, Masahiro, et al.
Publicado: (2015)

Cell cycle progression mechanisms: slower cyclin-D/CDK4 activation and faster cyclin-E/CDK2
por: Zhang, Wengang, et al.
Publicado: (2023)

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
por: Bolin, Sara, et al.
Publicado: (2018)

MEDB-80. CDK8 promotes stemness of MYC-driven medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential
por: Knudsen, Erik S., et al.
Publicado: (2016)

CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition
por: Kim, Sungsoo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_93q83mcdb5a94sbqvr2gfh4eqo